Literature DB >> 9033274

Immunological evidence for hypochlorite-modified proteins in human kidney.

E Malle1, C Woenckhaus, G Waeg, H Esterbauer, E F Gröne, H J Gröne.   

Abstract

Oxygen radicals and oxidatively modified proteins seem to participate in degenerative vascular and inflammatory diseases. Factors that contribute to the development of atherosclerosis, eg, oxidation of low-density lipoproteins (LDLs), may also contribute to glomerulosclerosis. Although the nature of the in vivo oxidants remains unknown, recent findings indicated that the myeloperoxidase (MPO)-H2O2-halide system could play an important role in modification of (lipo)proteins in human tissues. MPO, the enzyme responsible for hypochlorite (HOCl/OCl-) formation, is present in human atherosclerotic lesions and in inflammatory conditions. In the present study, MPO was identified by Western blot analysis and immunohistochemical technique in diseased human kidney either with primarily sclerotic or inflammatory lesions. Furthermore, the presence of HOCl-modified proteins was demonstrated in diseased renal tissues using a specific monoclonal antibody (clone 2D10G9), raised against HOCl-modified LDL, that does not cross-react with native LDL or Cu(2+)-, 4-hydroxynonenal-, or malondialdehyde-modified LDL. The antibody recognized HOCl-modified proteins in glomerular and tubulointerstitial inflammatory and fibrotic lesions and pronounced immunostaining was demonstrated in mononuclear cells. LDL or human serum albumin oxidized by HOCl in vitro, but not native LDL or human serum albumin, effectively competed with epitopes in diseased kidney for antibody binding. Western blot analysis in diseased kidney protein samples revealed at least two major proteins recognized by the anti-HOCl-modified protein monoclonal antibody. Densitometric evaluation of immunoreactive bands obtained under these conditions demonstrated that expression of HOCl-modified proteins is tightly coupled to expression of immunoreactive MPO in the same tissue samples. From our studies it is proposed that oxidation of proteins by HOCl might be a leading event in glomerular and tubulointerstitial injury. By this mechanism, mononuclear cells, a permanent source for MPO, may play a key role in the development of nephrosclerosis, glomerulo-clerosis, and tubulointerstitial fibrosis, respectively.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9033274      PMCID: PMC1858262     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  60 in total

1.  Visualization of binding and uptake of oxidized low density lipoproteins by cultured mesangial cells.

Authors:  H S Lee; H I Koh
Journal:  Lab Invest       Date:  1994-08       Impact factor: 5.662

Review 2.  Macrophages and renal disease.

Authors:  H Van Goor; G Ding; D Kees-Folts; J Grond; G F Schreiner; J R Diamond
Journal:  Lab Invest       Date:  1994-10       Impact factor: 5.662

Review 3.  The role of lipids in nephrosclerosis and glomerulosclerosis.

Authors:  E F Gröne; A K Walli; H J Gröne; B Miller; D Seidel
Journal:  Atherosclerosis       Date:  1994-05       Impact factor: 5.162

4.  Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum.

Authors:  K Kotani; M Maekawa; T Kanno; A Kondo; N Toda; M Manabe
Journal:  Biochim Biophys Acta       Date:  1994-11-17

5.  Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis?

Authors:  E Maggi; R Bellazzi; F Falaschi; A Frattoni; G Perani; G Finardi; A Gazo; M Nai; D Romanini; G Bellomo
Journal:  Kidney Int       Date:  1994-03       Impact factor: 10.612

6.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions.

Authors:  A Daugherty; J L Dunn; D L Rateri; J W Heinecke
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

7.  Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury.

Authors:  D C Wheeler; R S Chana; N Topley; M M Petersen; M Davies; J D Williams
Journal:  Kidney Int       Date:  1994-06       Impact factor: 10.612

8.  Reactive oxygen species and platelet-activating factor synthesis in age-related glomerulosclerosis.

Authors:  P Ruiz-Torres; M Gonzalez-Rubio; F J Lucio-Cazaña; A Ruiz-Villaespesa; M Rodriguez-Puyol; D Rodriguez-Puyol
Journal:  J Lab Clin Med       Date:  1994-10

9.  Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.

Authors:  T J Neale; P P Ojha; M Exner; H Poczewski; B Rüger; J L Witztum; P Davis; D Kerjaschki
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

10.  Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation.

Authors:  L J Hazell; J J van den Berg; R Stocker
Journal:  Biochem J       Date:  1994-08-15       Impact factor: 3.857

View more
  29 in total

1.  Advanced oxidation protein products activate intrarenal renin-angiotensin system via a CD36-mediated, redox-dependent pathway.

Authors:  Wei Cao; Jie Xu; Zhan Mei Zhou; Guo Bao Wang; Fan Fan Hou; Jing Nie
Journal:  Antioxid Redox Signal       Date:  2012-07-30       Impact factor: 8.401

2.  Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.

Authors:  Richard A Maki; Michael Holzer; Khatereh Motamedchaboki; Ernst Malle; Eliezer Masliah; Gunther Marsche; Wanda F Reynolds
Journal:  Free Radic Biol Med       Date:  2019-06-06       Impact factor: 7.376

3.  Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver.

Authors:  K E Brown; E M Brunt; J W Heinecke
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

4.  Hypochlorite-induced structural modifications enhance the chaperone activity of human α2-macroglobulin.

Authors:  Amy R Wyatt; Janet R Kumita; Richard W Mifsud; Cherrie A Gooden; Mark R Wilson; Christopher M Dobson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 11.205

5.  Myeloperoxidase-derived oxidants selectively disrupt the protein core of the heparan sulfate proteoglycan perlecan.

Authors:  Martin D Rees; John M Whitelock; Ernst Malle; Christine Y Chuang; Renato V Iozzo; Anastasia Nilasaroya; Michael J Davies
Journal:  Matrix Biol       Date:  2009-09-27       Impact factor: 11.583

6.  Neutralization of X4- and R5-tropic HIV-1 NL4-3 variants by HOCl-modified serum albumins.

Authors:  Svenja Polzer; Melanie van Yperen; Martin Kirst; Birco Schwalbe; Heiner Schaal; Michael Schreiber
Journal:  BMC Res Notes       Date:  2010-06-02

7.  Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus.

Authors:  Henda Bouali; Paul Nietert; Tamara M Nowling; Janardan Pandey; Mary Anne Dooley; Glinda Cooper; John Harley; Diane L Kamen; Jim Oates; Gary Gilkeson
Journal:  J Rheumatol       Date:  2007-09-15       Impact factor: 4.666

Review 8.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 9.  Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease.

Authors:  Daryl M Okamura; Jonathan Himmelfarb
Journal:  Pediatr Nephrol       Date:  2009-05-07       Impact factor: 3.714

10.  Roles of the hemostatic system and neutrophils in liver injury from co-exposure to amiodarone and lipopolysaccharide.

Authors:  Jingtao Lu; Robert A Roth; Ernst Malle; Patricia E Ganey
Journal:  Toxicol Sci       Date:  2013-08-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.